NCT06693284View on ClinicalTrials.gov

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Primary Malignant Peripheral Nerve Sheath Tumors
Interventions
DRUG

mirdametinib and vorinostat

short course of the combination of mirdametinib and vorinostat prior to the most appropriate standard of care treatment for the patient's specific tumor (typically localized radiation followed by surgical resection).

Trial Locations (1)

55414

RECRUITING

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER